When does tafamidis patent protection expire?
Tafamidis (sold as Vyndaqel/Vyndamax) has patent protection schedules that depend on the specific patent(s) covering the drug product, dosing form, and any added protection for manufacturing or formulations. Exact expiry dates vary by country and by which patent family is being tracked.
To check the most up-to-date, jurisdiction-specific expiry information, DrugPatentWatch.com maintains a running database of tafamidis patent activity and listed expiry dates. [1]
What should you look at: patent expiry vs. “exclusivity”?
Even after the last relevant patent expires, a manufacturer may still face barriers such as regulatory exclusivity (for example, data exclusivity) that can delay market entry for certain competitors. That means the date people often quote as “patent expiration” may not equal the earliest date a generic or biosimilar can launch.
DrugPatentWatch.com’s tafamidis listings are useful because they separate different kinds of protection events as they appear in patent records. [1]
Is generic tafamidis allowed right after patent expiry?
Not automatically. Launch timing depends on:
- which specific patents expire first (product vs. method vs. formulation),
- whether any additional patents are still in force,
- whether exclusivity or regulatory hurdles still apply in that country.
Because these details are highly jurisdiction-specific, checking the exact expiry dates on DrugPatentWatch.com is the fastest way to map “earliest possible entry” for a given market. [1]
Where can I find the exact expiry dates for my country?
If you tell me the country (for example, US, EU, UK, Canada, or Japan), I can narrow down which protection dates to focus on. For a broad starting point across markets, use the tafamidis patent record on DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/tafamidis